ES2081913T3 - Procedimiento para la expresion de proteinas heterologas fusionadas en e. coli, utilizacion de las mismas, vectores de expresion y cepas recombinantes. - Google Patents

Procedimiento para la expresion de proteinas heterologas fusionadas en e. coli, utilizacion de las mismas, vectores de expresion y cepas recombinantes.

Info

Publication number
ES2081913T3
ES2081913T3 ES90202108T ES90202108T ES2081913T3 ES 2081913 T3 ES2081913 T3 ES 2081913T3 ES 90202108 T ES90202108 T ES 90202108T ES 90202108 T ES90202108 T ES 90202108T ES 2081913 T3 ES2081913 T3 ES 2081913T3
Authority
ES
Spain
Prior art keywords
expression
coli
proteins
fused
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90202108T
Other languages
English (en)
Inventor
Perez Lidia Ines Novoa
Lahera Jorge A Machado
Maso Julio Raul Fernandez
Fuentes Jesus V Benitez
Diaz Ramon Emilio Narciandi
Reinoso Jose Luis Rodriquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CIGB
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
CIGB
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CIGB, Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical CIGB
Application granted granted Critical
Publication of ES2081913T3 publication Critical patent/ES2081913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION ES RELATIVA AL CAMPO DE LA BIOTECNOLOGIA Y EN PARTICULAR AL USO DE TECNOLOGIA DE RECOMBINACION DE DNA PARA LA PRODUCCION DE PROTEINAS HETEROLOGAS. EL OBJETO TECNICO DE ELLA ES DESARROLLAR UN METODO ALTAMENTE EFICIENTE PARA LA EXPRESION DE GENES HETEROLOGOS DE FORMA FUSIONADA EN "ESCHERICHIA COLI", LOS CUALES SE CODIFICAN POR PROTEINAS LAS CUALES PUEDEN SER FACILMENTE PURIFICADAS DEBIDO AL HECHO DE QUE SON SINTETIZADAS EN FORMA SOLUBLE EN EL CITOPLASMA CELULAR. PARA CONSEGUIR ESTO, SE USA UN VECTOR DE EXPRESION, EL CUAL CONTIENE UNA SECUENCIA ESTABILIZADORA LA CUAL SE CODIFICA SOLO PARA LOS PRIMEROS 58 AMINO ACIDOS PERTENECIENTES AL EXTREMO N-TERMINAL DE LA PROTEINA HUMANA INTERLEUKIN-2, LA CUAL ESTA BAJO EL PROMOTOR TRIPTOFANO DEL ACTUAL "ESCHERICHIA COLI". ESTE VECTOR CONTIENE ADEMAS EL GEN PARA RESISTIR LA AMPICILINA COMO UNA MARCA DE SELECCION Y EL TERMINADOR DEL ION DE TRANSCRIPCION DEL BACTERIOFAGO T4. EN PARTICULAR LOS GENES LOS CUALES SE CODIFICAN POR LAS PROTEINAS ANTIGENAS DEL VIRUS DE INMUNODEFIENCIA HUMANA (VIH 1 Y 2) SERAN CLONADOS EN EL, OBTENIENDOSE ALTOS NIVELES DE EXPRESION DE DICHA PROTEINA DE LOS LINAJES TRANSFORMADOS DE LA BACTERIA "ESCHERICHIA COLI". EL METODO, EL CUAL ES EL OBJETO DE LA PRESENTE INVENCION, SE PUEDE EMPLEAR PARA LA EXPRESION DE PROTEINAS HETEROLOGAS, RECOMBINADAS EN ALTOS NIVELES, SINTETIZADAS EN FORMA INSOLUBLE Y FUSIONADA EN "E. COLI", LAS CUALES SE PUEDEN USAR EN LA INDUSTRIA FARMACEUTICA PARA OBTENER PREPARACIONES DE VACUNA O EN EL DESARROLLO DE SISTEMAS DE DIAGNOSTICOS, EN LA INDUSTRIA ALIMENTARIA, EN AGRICULTURA,ETC
ES90202108T 1989-08-03 1990-08-02 Procedimiento para la expresion de proteinas heterologas fusionadas en e. coli, utilizacion de las mismas, vectores de expresion y cepas recombinantes. Expired - Lifetime ES2081913T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU89149A CU22222A1 (es) 1989-08-03 1989-08-03 Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes

Publications (1)

Publication Number Publication Date
ES2081913T3 true ES2081913T3 (es) 1996-03-16

Family

ID=5459457

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90202108T Expired - Lifetime ES2081913T3 (es) 1989-08-03 1990-08-02 Procedimiento para la expresion de proteinas heterologas fusionadas en e. coli, utilizacion de las mismas, vectores de expresion y cepas recombinantes.

Country Status (6)

Country Link
EP (1) EP0416673B1 (es)
JP (1) JPH04158797A (es)
AT (1) ATE130370T1 (es)
CU (1) CU22222A1 (es)
DE (1) DE69023580T2 (es)
ES (1) ES2081913T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4002636A1 (de) * 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh Expression von hiv1- und 2-polypeptiden und deren verwendung
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6929791B2 (en) 1998-07-16 2005-08-16 Institut Pasteur Peptides of IL-2 and derivatives thereof
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment
US7264809B1 (en) 1998-10-16 2007-09-04 Immunex Corporation Methods of inhibiting platelet activation and recruitment
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002314111A1 (en) * 2001-06-15 2003-01-02 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2007141650A2 (en) * 2006-01-17 2007-12-13 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
DE3636903A1 (de) * 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
DE3688051T2 (de) * 1985-12-17 1993-06-24 Akzo Nv Immunochemisches reagenz.
EP0345792A3 (en) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins

Also Published As

Publication number Publication date
EP0416673A1 (en) 1991-03-13
DE69023580T2 (de) 1996-04-11
DE69023580D1 (de) 1995-12-21
CU22222A1 (es) 1995-01-31
EP0416673B1 (en) 1995-11-15
ATE130370T1 (de) 1995-12-15
JPH04158797A (ja) 1992-06-01

Similar Documents

Publication Publication Date Title
EA199700244A1 (ru) Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат
KR950000300B1 (ko) 융합 단백질의 제조방법
ES2081913T3 (es) Procedimiento para la expresion de proteinas heterologas fusionadas en e. coli, utilizacion de las mismas, vectores de expresion y cepas recombinantes.
CA2195799C (en) Bacterial production of hydrophobic polypeptides
ES2122257T3 (es) Proteinas de fusion de la toxina del antrax y usos de las mismas.
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
DE3584053D1 (de) Gentechnologisches verfahren zur herstellung von hirudinen und mittel zur durchfuehrung dieses verfahrens.
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
DE69229221D1 (de) Expression rekombinanter proteine in attenuierten bakterien
NO974812D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
PT97965A (pt) Processo para a preparacao de novos fragmentos peptidicos, de sequencias de dna que os codificam,de moleculas de dna que as contem e plantas transgenicas que compreendem tais moleculas
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
NO902251D0 (no) Fremstilling av gonorrheiske p1-proteiner og vaksiner.
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
ES2290156T3 (es) Vector de expresion y secrecion del alfa interferon humano y procedimiento para producir alfa interferon humano empleando el anterior.
Russell-Harde et al. The use of zwittergent 3-14 in the purification of recombinant human interferon-β ser17 (Betaseron)
DE3671916D1 (de) Mit einem herpes-simplex-virus-gen inseriertes rekombinantes plasmid.
ES2136062T3 (es) Plasmido pctd aislado de chlamydia trachomatis serotipo d, genes y proteinas codificados por el mismo; plasmidos recombinantes para la expresion de dichos genes en sistemas heterologos como proteinas recombinantes de fusion, preparacion de dichas proteinas recombinantes y ...
ES2079493T3 (es) Proteina de membrana externa p1 y peptidos haemophilus influenzae tipo b.
ATE105864T1 (de) Rekombinante plasmide, die zur expression von heterologen proteinen in bacillus verwendet werden können.
ATE132192T1 (de) Rekombinantes produkt
JPS615096A (ja) 新規ポリペプチドおよびその製造法
Sekine et al. Expression of HTLV-I gag protein in Escherichia coli
ES2120409T3 (es) Nuevos vectores de expresion y metodos para la produccion de proteinas intracelulares.
NO902491D0 (no) Proteiner, vaksiner og nukleinsyrer.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 416673

Country of ref document: ES